

RIGHT Statement Extensions Translations Publications Endorsement Ab

Home / RIGHT Statement / RIGHT Checklist

RIGHT Checklist

	RIGHT (Reporting Items for practice Guidelines in HealThcare) Checklist				
22 Sections/topics and 35 Items		Asse ssme nt	P ag e(s)	N ot e(s)	
Se cti on/ top ic	No./ Item				
Basi	Basic information				
Title/s	subtitle				
1a	Identify the report as a guideline, that is, with "guideline(s)" or "recommendation(s)" in the title.	Ye s No Un cle ar			
1b	Describe the year of publication of the guideline.	Ye s No Un cle ar			
1c	Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention, or others.	Ye s No Un cle ar			
Execu	Executive summary				
2	Provide a summary of the recommendations contained in the guideline.	Ye s			

01/2023, 12	:59 RIGHT Ch	ecklist - Right
		Un cle ar
Abbro	eviations and acronyms	
3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable.	Ye s No Un cle ar
Corre	sponding developer	
4	Identify at least 1 corresponding developer or author who can be contacted about the guideline.	✓ Ye s No Un cle ar
Back	ground	
Brief	description of the health problem(s)	
5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.	✓ Ye s No Un cle ar
Aim(s	s) of the guideline and specific objectives	· · ·
6	Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.	Ye s No Un cle ar
Targe	t populations	
7a	Describe the primary population(s) that is affected by the recommendation(s) in the guideline.	✓ Ye s No Un cle ar
7b	Describe any subgroups that are given special consideration in the guideline.	Ye s ○ No ○ Un cle ar
End ເ	isers and settings	
8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and	Ye s No Un cle ar

RIGHT Che	ecklist - Right
policymakers) and other potential users of the guideline.	
Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities.	Ye s No Un cle ar
eline development groups	
Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewer, systematic review team, and methodologists).	Ye s No Un cle ar
List all individuals involved in developing the guideline, including their title, role(s) and institutional affiliation(s).	Ye s No Un cle ar
ence	
h care questions	
State the key questions that were the basis for the recommendations in PICO (population, intervention, comparator, and outcome) or other format as appropriate.	Ye s No Un cle ar
Indicate how the outcomes were selected and sorted.	Ye s No Un cle ar
matic reviews	
Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.	Ye s No Un cle ar
If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and	✓ Ye s ○ No ○ Un
	guideline. Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities. eline development groups Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewer, systematic review team, and methodologists). List all individuals involved in developing the guideline, including their title, role(s) and institutional affiliation(s). ence h care questions State the key questions that were the basis for the recommendations in PICO (population, intervention, comparator, and outcome) or other format as appropriate. Indicate how the outcomes were selected and sorted. ematic reviews Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used. If the guideline developers used existing systematic reviews, reference these and describe how those

12	Describe the approach used to assess the certainty of the body of evidence.	Ye s No Un cle ar	
Reco	mmendations		
Reco	mmendations		
13a	Provide clear, precise, and actionable recommendations.	Ye s No Un cle ar	
13b	Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.	Ye s No Un cle ar	
13c	Indicate the strength of recommendations and the certainty of the supporting evidence.	Ye s No Un cle ar	
Ratio	nale/explanation for recommendations		
14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.	 ✓ Ye S No Un cle ar 	
14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.	 ✓ Ye S No Un cle ar 	
14c	Describe other factors taken into consideration when formulating the recommendations, such as equity, feasibility and acceptability.	 ✓ Ye S No Un cle ar 	
Evidence to decision processes			
15	Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such	Ye s No	

/2023,12	2:59 RIGHT Ch	ecklist - Right
	as how consensus was defined and achieved and whether voting was used).	Un cle ar
Revi	ew and quality assurance	
Exter	nal review	
16	Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.	 Ye S ✓ No Un cle ar
Quali	ty assurance	
17	Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.	Ye s No Un cle ar
Fund	ling, declaration and management of interests	
Fund	ing source(s) and role(s) of the funder	
18a	Describe the specific sources of funding for all stages of guideline development.	 ✓ Ye S No Un cle ar
18b	Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.	 Ye S ✓ No Un cle ar
Decla	aration and management of interest	
19a	Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.	Ye s No Un cle ar
19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.	Ye s No Un cle ar
Othe	r information	
Acce	SS	
20	Describe where the guideline, its appendices, and other related documents can be accessed.	Ye s No

	Norr Chockist Right				
		Un cle ar			
Sugg	estions for further research				
21	Describe the gaps in the evidence and/or provide suggestions for future research.	Ye s No Un cle ar			
Limita	Limitations of the guideline				
22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations.	Ye s No Un cle ar			
Reference: Chen Y, Yang K, Marušić A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement[J]. Annals of Internal Medicine, 2017, 166(2):128-132. <u>https://doi.org/10.7326/M16-1565</u> Official Website: <u>http://www.right-statement.org/</u>					

- Our sponsors, supporters and partners -









Copyright 2015 - 2023 RIGHT Statement. All rights reserved.